Prevention and Management of Hepatitis B Virus Reactivation

DOI IR (HANDLE) Web Site Open Access
  • Gotoh Kazuhito
    Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University

Bibliographic Information

Other Title
  • Ｂ型肝炎ウイルスの再活性化の現状
  • Bガタ カンエンウイルス ノ サイカッセイカ ノ ゲンジョウ

Search this article

Description

Globally, it is estimated that around 1 in every 3 individuals may have been exposed to hepatitis B virus(HBV) infection. In addition, population of 6％ are chronic carriers and over 600,000 people die each year from acute hepatitis, liver cirrhosis or hepatocellular carcinoma due to HBV infection. Recently, HBV reactivation associated with immune-suppressive and biological therapies is emerging to be an important cause of morbidity and mortality in patients with prior exposure to HBV infection. With the advent of newer and emerging forms of cancer chemotherapy, immunosuppressive or biologic therapies, it has become important to understand the mechanisms whereby certain therapies are more prone to HBV reactivation. In this article, we summarize the mechanism of HBV reactivation associated with immune-suppressive and biological therapies.

Journal

  • 福岡醫學雜誌

    福岡醫學雜誌 110 (1), 1-7, 2019-03-25

    Fukuoka Medical Association

Keywords

Details 詳細情報について

Report a problem

Back to top